tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Fate Therapeutics (FATE) and Kezar Life Sciences (KZR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFEResearch Report), Fate Therapeutics (FATEResearch Report) and Kezar Life Sciences (KZRResearch Report).

Pfizer (PFE)

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $57.00. The company’s shares closed last Monday at $51.88.

According to TipRanks.com, Schott is a 2-star analyst with an average return of 0.2% and a 51.7% success rate. Schott covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Coherus Biosciences, and Idexx Laboratories.

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $58.92, which is a 14.5% upside from current levels. In a report issued on June 26, Barclays also maintained a Hold rating on the stock with a $52.00 price target.

See today’s best-performing stocks on TipRanks >>

Fate Therapeutics (FATE)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Fate Therapeutics, with a price target of $109.00. The company’s shares closed last Monday at $26.25, close to its 52-week low of $17.10.

According to TipRanks.com, Goldstein is a 3-star analyst with an average return of 1.3% and a 35.2% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fate Therapeutics with a $70.43 average price target.

Kezar Life Sciences (KZR)

Jefferies analyst Maury Raycroft maintained a Buy rating on Kezar Life Sciences today and set a price target of $20.00. The company’s shares closed last Monday at $5.78, close to its 52-week low of $4.31.

According to TipRanks.com, Raycroft is a 2-star analyst with an average return of 0.0% and a 36.6% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Aurinia Pharmaceuticals, and Mirati Therapeutics.

Kezar Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $18.33, implying a 209.6% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PFE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed